Subscribe To
Processa pharmaceuticals to present pcs12852 gastroparesis results at the digestive disease week 2023 annual meeting
pcs12852 Shown to be Safe and Efficacious in Phase 2 Proof-of-Concept Trial in Gastroparesis Patients <...
April 28, 2023, 12:15 pm
Processa pharmaceuticals to present pcs12852 gastroparesis results at the digestive disease week 2023 annual meeting
HANOVER, MD, April 28, 2023 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage ...
April 28, 2023, 8:15 am